The endothelin axis in urologic tumors: mechanisms of tumor biology and therapeutic implications (Q36352082)

13 August 2017

1 reference

title

The endothelin axis in urologic tumors: mechanisms of tumor biology and therapeutic implications (English)

1 reference

13 August 2017

Edwin Herrmann

1

1 reference

13 August 2017

Martin Bögemann

2

1 reference

13 August 2017

Stefan Bierer

3

1 reference

13 August 2017

Elke Eltze

4

1 reference

13 August 2017

Lothar Hertle

5

1 reference

13 August 2017

Christian Wülfing

6

1 reference

13 August 2017

1 January 2006

1 reference

Expert Review of Anticancer Therapy

13 August 2017

1 reference

13 August 2017

6

1 reference

13 August 2017

1

1 reference

13 August 2017

73-81

1 reference

A novel potent vasoconstrictor peptide produced by vascular endothelial cells

13 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.73

Cloning and functional expression of human cDNA for the ETB endothelin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.73

The endothelin axis: emerging role in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.73

Endothelin-1: a multifunctional molecule in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.73

Role of endothelin-1 in neovascularization of ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.73

Endothelin-1-, endothelin-A-, and endothelin-B-receptor expression is correlated with vascular endothelial growth factor expression and angiogenesis in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.73

Growth regulatory properties of endothelins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.73

Endothelin attenuates apoptosis in human smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.73

New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.73

Factors regulating the growth of metastatic cancer in bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.73

Metastasis to bone: causes, consequences and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.73

Molecular mechanisms of osteolytic bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.73

Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.73

Endothelium-derived factors as paracrine mediators of prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.73

Hypoxia induces endothelin gene expression and secretion in cultured human endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.73

Raised endothelin 1 levels in patients with colorectal liver metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.73

Estimating the world cancer burden: Globocan 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.73

Expression of endothelin-A-receptor predicts unfavourable response to neoadjuvant chemotherapy in locally advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.73

Expression of endothelin 1 and endothelin A receptor in HPV-associated cervical carcinoma: new potential targets for anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.73

Pharmacokinetics and pharmacodynamic effects of ABT-627, an oral ETA selective endothelin antagonist, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.73

Increased endothelin-1 in colorectal cancer and reduction of tumour growth by ET(A) receptor antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.73

The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.73

Detection of endothelin immunoreactivity and mRNA in pulmonary tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.73

Expression of the endothelin-B receptor in pigment cell lesions of the skin. Evidence for its role as tumor progression marker in malignant melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.73

An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.73

A selective endothelin ETA antagonist, BQ-123, inhibits 125I-endothelin-1 (125I-ET-1) binding to human meningiomas and antagonizes ET-1-induced proliferation of meningioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.73

Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.73

Clinical trials in metastatic prostate cancer--has there been real progress in the past decade?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.73

Endothelin-1 inhibits apoptosis in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.73

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.73

Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.73

Endothelins in the urinary tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.73

21 January 2018

Cancer and the kidney

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.73

Endothelin axis expression is markedly different in the two main subtypes of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.73

Endothelin B receptor blockade inhibits dynamics of cell interactions and communications in melanoma cell progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.73

Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.73

β-Catenin activates the growth factor endothelin-1 in colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.1.73

21 January 2018

Identifiers

DOI

10.1586/14737140.6.1.73

1 reference

13 August 2017

1 reference